The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwNHL 2025 | Classifying lymphoid malignancies: including AI-based pathology, multimodal data, and liquid biopsy
Laurence de Leval, MD, PhD, Lausanne University Hospital, Lausanne, Switzerland, comments on the potential incorporation of artificial intelligence (AI)-based pathology, multimodal data integration, and liquid biopsy into future classifications of lymphoid malignancies. She states that while novel data is being generated, it’s too early to determine what will be included, but emphasizes that classification should prioritize clinically relevant information that influences therapy. This interview took place at the 22nd International Workshop on Non-Hodgkin Lymphoma (iwNHL 2025), held in Cambridge, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, you know, the aim of classification is to define disease and to set the language that we commonly use. Of course, to define those diseases we need to have the tools to assess the lesions, the pathology, and to find out what it is. Of course, future classification, they tend to incorporate novel knowledge, novel data. But the bottom line is what will be incorporated are things that are clinically relevant at this point or may influence therapy...
Well, you know, the aim of classification is to define disease and to set the language that we commonly use. Of course, to define those diseases we need to have the tools to assess the lesions, the pathology, and to find out what it is. Of course, future classification, they tend to incorporate novel knowledge, novel data. But the bottom line is what will be incorporated are things that are clinically relevant at this point or may influence therapy. So it’s probably a bit early to answer this question. I think those data are starting to be generated and we will see the outcome, how they can translate into kind of probably simplified assays to capture whatever is important that will be concluded from these in-depth analyses. But another important point, classification, especially one of the WHO dogma is to produce a manual that should be applied worldwide. That means it should be accessible to people in lower resource conditions. So these very sophisticated spatial techniques, I mean, in no way will they be introduced to define something new or to be used in daily practice. Not yet.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
